PT  - JOURNAL ARTICLE
AU  - SUIMON, YUKA
AU  - KASE, SATORU
AU  - MIURA, ICHIRO
AU  - ISHIJIMA, KAN
AU  - ISHIDA, SUSUMU
TI  - Alteration of Cell Surface Markers CD38 and CD138 in Lymphoproliferative Disorders in the Ocular Adnexa
AID  - 10.21873/anticanres.14158
DP  - 2020 Apr 01
TA  - Anticancer Research
PG  - 2019--2023
VI  - 40
IP  - 4
4099  - http://ar.iiarjournals.org/content/40/4/2019.short
4100  - http://ar.iiarjournals.org/content/40/4/2019.full
SO  - Anticancer Res2020 Apr 01; 40
AB  - Background/Aim: CD38 is a cell surface marker commonly present in plasma cells and activated T cells, while CD138 is a representative plasma cell marker. The aim of this study was to describe the expression of cell surface markers including CD38 and CD138, in the tumors of patients with IgG4-related ophthalmic disease (IgG4-ROD) and extranodal marginal zone B-cell lymphoma (EMZL) of the ocular adnexa. Materials and Methods: Twenty-four consecutive patients of whom 12 had IgG4-ROD and 12 EMZL were enrolled in this study. Medical records were reviewed for flow cytometry (FCM) results on conventional T-cell markers, B-cell markers, CD38 and CD138. Results: Positive rates of T-cell markers, CD38 and CD138 were significantly higher in IgG4-ROD than in EMZL (p<0.01 and p<0.05, respectively). Conclusion: Our FCM results on CD38 and CD138 showed that the lymphocyte populations were different between IgG4-ROD and EMZL, which may reflect the different pathophysiology of the two diseases.